Working together to deliver cell and gene therapies for people impacted by serious diseases Learn More Our inspiration Learn More Pipeline Explore R&D EB-101 In Phase 3 development. Autologous gene-corrected cell therapy for patients with RDEB. Learn More ABO-102 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). Learn More ABO-50X Exploring the potential of ABO-50X for the treatment of genetic eye disorders. Learn More Latest News Mar 29, 2023 Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update View Press Release Mar 24, 2023 Abeona Therapeutics Announces New Employee Inducement Grants View Press Release Mar 16, 2023 Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting View Press Release View All Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
